Fri news: Lilly’s powerful new supercomputer goes live in AI push. Novartis completes acquisition of Avidity. Merck’s bladder cancer combo aces another trial. How PBM reforms could push drugmakers into the pricing spotlight. —https://bit.ly/3JeBlY5
27.02.2026 17:17 — 👍 0 🔁 0 💬 0 📌 0Thurs news: BMS ADC phase 3 breast cancer trial success. Lilly bests Novo in weight loss again. Viatris cutting up to 10% of global workforce. Boehringer bets up to $500M on immunology program. —https://bit.ly/3JeBlY5
26.02.2026 17:07 — 👍 0 🔁 0 💬 0 📌 0Wed news: GSK to acquire 35Pharma in $950M deal. Novo Nordisk inks $2.1B pact to boost oral drug delivery prowess. Alkermes CEO retiring. Astellas bets on Vir cancer drug. —https://bit.ly/3JeBlY5
25.02.2026 17:09 — 👍 0 🔁 0 💬 0 📌 0Tue news: Novo slashes US GLP-1 prices. Roche seeks antibiotic partner. GSK siRNA deal. 5 key medtech takeaways from the Supreme Court tariff ruling. —https://bit.ly/3JeBlY5
24.02.2026 17:22 — 👍 0 🔁 0 💬 0 📌 0Mon news: Novo’s CagriSema loses phase 3 battle with Lilly. Gilead buying Arcellx for up to $7.8B. JNJ reports Tremfya data in ulcerative colitis. What next for pharma as SCOTUS strikes down Trump tariffs? —https://bit.ly/3JeBlY5
23.02.2026 17:15 — 👍 0 🔁 0 💬 1 📌 0Fri news: Lilly’s Omvoh achieves 91% Crohn’s remission at 3 years. AZ’s Calquence combo wins FDA nod. Insmed’s $1B Brinsupri sales projection. ACIP meeting delayed. Biohaven charts comeback by taking obesity path. —https://bit.ly/3JeBlY5
20.02.2026 17:20 — 👍 0 🔁 0 💬 0 📌 0Thurs news: FDA letter blasts JNJ Tremfya ad claims. Hims & Hers GLP-1 pill gambit backfires. Merck and Mayo Clinic team up on AI drug dev. FDA ending two trial default for approvals. An Alzheimer’s startup emerges with $175M in venture backing. —https://bit.ly/3JeBlY5
19.02.2026 17:28 — 👍 0 🔁 0 💬 0 📌 0Wed news: FDA reverses course on Moderna flu vaccine. Novartis heads to FDA with Rhapsido. Medtronic completes first US Hugo case. How AI could affect pharma jobs. FDA starts review of BMS's 'celmod' for multiple myeloma. —https://bit.ly/3JeBlY5
18.02.2026 17:15 — 👍 1 🔁 0 💬 0 📌 0Tue news: Lilly looks to India as a global export hub. Sanofi-Teva IBD opportunity. Medtronic slides admit tariff impacts. Danaher to buy Masimo for $9.9B. Novo wins EU approval for higher-dose Wegovy. —https://bit.ly/3JeBlY5
17.02.2026 17:35 — 👍 0 🔁 0 💬 0 📌 0Fri news: All eyes on Vertex kidney franchise. Novo plans Wegovy vials. Lundbeck migraine trial success. Lilly prepares $1b+ orforglipron stock ahead of approval. Baxter dives on Q4 miss. —https://bit.ly/3JeBlY5
13.02.2026 17:21 — 👍 0 🔁 0 💬 0 📌 0Thurs news: Sanofi ousts CEO Paul Hudson. Oral Wegovy bringing in 1000s of new patients. IRA boosts Medicare drug coverage. Zimmer to reorganize US salesforce. AbbVie sues over Botox inclusion in IRA. —https://bit.ly/3JeBlY5
12.02.2026 16:54 — 👍 0 🔁 0 💬 0 📌 0Wed news: Gilead posts strong earnings. Latest biopharma hiring outlook. FDA refuses to review Moderna mRNA flu vaccine. Xarelto stroke trial halted. Clinicians finding pharmacies digital interaction inept. —https://bit.ly/3JeBlY5
11.02.2026 16:34 — 👍 0 🔁 0 💬 0 📌 0Tue news: AstraZeneca continues earnings ambitions. Novo patent suit over Hims’ Wegovy copy. Stryker releases handheld knee robot. CVS profits hit nearly $3B. FDA calls out Novo TV ad as ‘false or misleading’. —https://bit.ly/3JeBlY5
10.02.2026 16:55 — 👍 0 🔁 0 💬 0 📌 0Mon news: Lilly buys Orna to enter CAR-T arena. Takeda-Iambic AI partnership. Novartis building research facility in San Diego. New Roche MS data. BD slides despite earnings beat. —https://bit.ly/3JeBlY5
09.02.2026 17:21 — 👍 0 🔁 0 💬 0 📌 0Fri news: Biogen earnings beat. Obesity space abuzz. Psychedelic drugs. Big Pharma CEOs set on growth. Novo shares rebound. —https://bit.ly/3JeBlY5
06.02.2026 17:38 — 👍 0 🔁 0 💬 0 📌 0Thurs news: Novo will take legal action against Hims’ Wegovy pill copycat. Astellas tops expectations. BMS posts modest growth. JNJ corrects Impella heart pump issue. Biotech IPOs surging. —https://bit.ly/3JeBlY5
05.02.2026 17:30 — 👍 0 🔁 0 💬 0 📌 0Wed news: Novo shares tumble as CEO warns. Earnings from GSK, Lilly, and more. Novartis sticks with M&A strategy. Amgen resists pulling Tavneos from market. Medtronic to acquire CathWorks. —https://bit.ly/3JeBlY5
04.02.2026 16:46 — 👍 0 🔁 0 💬 0 📌 0Tue news: Pfizer’s Metsera GLP-1 bet generating weight loss in phase 2b. BMS and JNJ want to educate HCPs before milvexian data drop. PBMs hit by Trump rule. Merck tops Q4 estimates. Novo’s combo obesity shot meets trial goal. —https://bit.ly/3JeBlY5
03.02.2026 16:25 — 👍 1 🔁 0 💬 0 📌 0Mon news: Obesity market sales potential tightens. Sanofi’s troubled GCS inhibitor. FDA launches PreCheck program. GSK walks away from Wave RNA editing drug. Roche’s return to RNA continues. —https://bit.ly/3JeBlY5
02.02.2026 16:34 — 👍 0 🔁 0 💬 0 📌 0Fri news: AZ leans into obesity with China alliance. Amgen jilts Kyowa Kirin. Moderna offloads rare disease drug. Top medtech trends for 2026. Takeda lifts guidance. —https://bit.ly/3JeBlY5
30.01.2026 17:20 — 👍 0 🔁 0 💬 0 📌 0Thurs news: Roche and Sanofi earnings fail to excite. AZ vows China investment. Medtech M&A took off in second half of 2025. Tenpoint looks to launch presbyopia eyedrops after FDA nod. Hair loss biotech IPO. —https://bit.ly/3JeBlY5
29.01.2026 16:48 — 👍 0 🔁 0 💬 0 📌 0Wed news: Novo obesity/diabetes US ad spend double’s Lilly’s. Teva expects downturn in 2026. Lilly allies with gene-editing firm on hearing loss. Boehringer’s midstage kidney disease trial momentum. The newest 15 drugs facing IRA pricing cuts. —https://bit.ly/3JeBlY5
28.01.2026 17:09 — 👍 0 🔁 0 💬 0 📌 0Tue news: Roche obesity drug led to 22.5% weight loss in trial. China’s edge in early-stage drugmaking. 5 robotic surgery trends to watch. Boehringer IBD deal. Pfizer retains top spot in physician vaccine rankings. —https://bit.ly/3JeBlY5
27.01.2026 16:41 — 👍 0 🔁 0 💬 0 📌 0Mon news: Biopharma layoffs - what’s ahead for 2026. AZ keeps pause on UK R&D site. Express Scripts considering settlement with FTC. Intuitive pushes into cardiac robotic surgery. Merck no longer buying Revolution Medicines. —https://bit.ly/3JeBlY5
26.01.2026 16:56 — 👍 0 🔁 0 💬 0 📌 0Fri news: Sanofi Dupixent successor heads to FDA. Novo’s Wegovy pill launch wows. Big Pharma shops Chinese biotechs for GLP-1s. Bausch’s Xifaxan successor ph III failure. US withdraws from WHO. —https://bit.ly/3JeBlY5
23.01.2026 17:49 — 👍 0 🔁 0 💬 0 📌 0Thurs news: Lexicon opens path to $1B opportunity. Merck and CEPI join forces against Ebola. BMS pens solid tumor pact with Janux. FDA’s Feb 1 PreCheck launch date. Takeda neuro field force layoffs. —https://bit.ly/3JeBlY5
22.01.2026 17:29 — 👍 0 🔁 0 💬 0 📌 0Wed news: JNJ earnings. Pfizer CEO lays blame on RFK Jr. Astellas’ banner year. Roche raises NC manufacturing investment. GSK licenses Alteogen enzyme. —https://bit.ly/3JeBlY5
21.01.2026 17:32 — 👍 0 🔁 0 💬 0 📌 0Tue news: GSK buying Rapt for $2.2B for food allergy drug. Trump’s new tariff threats risk upending EU trade deal. Merck-Moderna vaccine sustains melanoma risk reduction. Possible RICO case against Lilly and Takeda. The latest biopharma AI deals. —https://bit.ly/3JeBlY5
20.01.2026 17:02 — 👍 0 🔁 0 💬 0 📌 0Fri news: Novo’s new Wegovy pill shows solid launch data. JPMHC takeaways. Legal questions swirl around new FDA priority review program. Sanofi rumored to be bidding to takeover Ocular Therapeutix. Trump’s new healthcare proposal and drugmakers. —https://bit.ly/3JeBlY5
16.01.2026 17:13 — 👍 0 🔁 0 💬 0 📌 0Thurs news: Boston Sci buying Penumbra for $14.5B. JPMHC: Astellas CEO talks Xtandi patent cliff. Lilly, Sanofi among delayed FDA priority reviews. FDA/EMA collab on AI drug development guidelines. JNJ’s case for earlier Tecvayli multiple myeloma use —https://bit.ly/3JeBlY5
15.01.2026 17:03 — 👍 0 🔁 0 💬 0 📌 0